A case of hidradenitis suppurativa complicated by necrotizing soft tissue infection.

Am J Emerg MedJun 18, 2026 (epub)
Case ReportEmergency MedicineDermatologyGeneral Surgery

Dhayashri Dhavapalani, Kaylah Maloney, Chifaa Bouzidi et al.

✦ AI-curated · Sources linked

Case in brief

A 28-year-old man with hidradenitis suppurativa on adalimumab presented with left axillary pain and swelling at a previous HS site. Initial examination showed localized erythema, but after 50 minutes, the erythema had rapidly extended, raising suspicion for necrotizing soft tissue infection (NSTI). Emergent surgery revealed purulent fluid and nonviable tissue. The patient had a prolonged recovery, requiring 25 days in the hospital.

Diagnostic / clinical pearl

In patients with hidradenitis suppurativa, subtle or nonspecific findings may obscure the diagnosis of necrotizing soft tissue infection, necessitating a high index of suspicion and frequent reassessment.

Why it matters

This case highlights the importance of recognizing that underlying skin conditions can complicate the clinical presentation of serious infections, emphasizing the need for timely surgical intervention.

Source

PubMed · PMID 42320420

Published in Am J Emerg Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Emergency Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.